Health Stock on the Rise
This stock could be a major success story in 2021.
Here's why.
Melissa B. Epperly, insider at Zentalis Pharmaceuticals
Melissa B. Epperly Insider Alerts

Get notified the next time Melissa B. Epperly buys or sells Zentalis Pharmaceuticals stock. Enter your email address below to get our daily insider buying and selling report.

Melissa B. Epperly Insider Information

Melissa is Chief Financial Officer at Zentalis Pharmaceuticals. She brings extensive experience as a senior financial executive in the life sciences industry. She most recently served as CFO at PsiOxus Therapeutics, a clinical-stage gene therapy cancer company, and prior to that, CFO and Head of Business Development at R-Pharm US, a commercial-stage oncology company. Previously, Melissa was a Director at Anchorage Capital Group, a credit-focused hedge fund; a Vice President at Goldman Sachs in equity research in New York and London where she built GS SUSTAIN; and a management consultant with Bain & Company focused on international and US based pharmaceutical clients and private equity. She began her career at Morgan Stanley in New York in healthcare investment banking. Melissa earned her MBA from Harvard Business School and BA in Biochemistry and Economics from the University of Virginia, where she graduated Phi Beta Kappa.

What is Melissa B. Epperly's net worth?

The estimated net worth of Melissa B. Epperly is at least $20.05 million as of August 18th, 2021. Ms. Epperly owns 258,400 shares of Zentalis Pharmaceuticals stock worth more than $20,054,424 as of November 30th. This net worth approximation does not reflect any other assets that Ms. Epperly may own. Learn More.

How old is Melissa B. Epperly?

Ms. Epperly is currently 43 years old. There are 5 older executives and no younger executives at Zentalis Pharmaceuticals. The oldest executive at Zentalis Pharmaceuticals is Dr. Dimitris Voliotis M.D., Sr. VP of Clinical Devel., who is 57 years old. Learn More.

How do I contact Melissa B. Epperly?

The corporate mailing address for Ms. Epperly and other Zentalis Pharmaceuticals executives is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. Zentalis Pharmaceuticals can also be reached via email at [email protected]

Has Melissa B. Epperly been buying or selling shares of Zentalis Pharmaceuticals?

Melissa B. Epperly has not been actively trading shares of Zentalis Pharmaceuticals in the last ninety days. Most recently, on Wednesday, August 18th, Melissa B. Epperly bought 1,326 shares of Zentalis Pharmaceuticals stock. The stock was acquired at an average cost of $52.00 per share, with a total value of $68,952.00. Following the completion of the transaction, the chief financial officer now directly owns 258,400 shares of the company's stock, valued at $13,436,800.

Who are Zentalis Pharmaceuticals' active insiders?

Zentalis Pharmaceuticals' insider roster includes Kimberly Blackwell (Director), Kevin Bunker (COO), Melissa Epperly (CFO), Cam Gallagher (Director), David Johnson (Director), Alexis Pinto (Insider), and Anthony Sun (CEO).

Are insiders buying or selling shares of Zentalis Pharmaceuticals?

In the last twelve months, Zentalis Pharmaceuticals insiders bought shares 1 times. They purchased a total of 1,326 shares worth more than $68,952.00. In the last twelve months, insiders at the sold shares 58 times. They sold a total of 1,308,728 shares worth more than $69,927,214.43. The most recent insider tranaction occured on November, 22nd when COO Kevin D Bunker sold 10,000 shares worth more than $759,900.00. Insiders at Zentalis Pharmaceuticals own 21.0 % of the company.

Information on this page was last updated on 11/22/2021.

Melissa B. Epperly Insider Trading History at Zentalis Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/18/2021Buy1,326$52.00$68,952.00258,400View SEC Filing Icon  
7/1/2021Sell3,083$51.27$158,065.41259,457View SEC Filing Icon  
6/1/2021Sell3,083$54.05$166,636.15260,357View SEC Filing Icon  
5/3/2021Sell3,083$59.24$182,636.92265,973View SEC Filing Icon  
4/5/2021Sell17,107$43.39$742,272.73280,347View SEC Filing Icon  
1/4/2021Sell3,083$51.91$160,038.53276,879View SEC Filing Icon  
12/7/2020Sell6,464$53.52$345,953.28288,020View SEC Filing Icon  
12/4/2020Sell7,220$50.98$368,075.60288,020View SEC Filing Icon  
12/2/2020Sell3,083$51.47$158,682.01293,746View SEC Filing Icon  
11/23/2020Sell3,083$46.58$143,606.14297,529View SEC Filing Icon  
4/7/2020Buy20,000$18.00$360,000.00297,529View SEC Filing Icon  
See Full Table

Melissa B. Epperly Buying and Selling Activity at Zentalis Pharmaceuticals

This chart shows Melissa B Epperly's buying and selling at Zentalis Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Zentalis Pharmaceuticals Company Overview

Zentalis Pharmaceuticals logo
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, as well as in Phase 1b clinical trial in combination with chemotherapy in patients with advanced ovarian cancer. The company also develops ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Read More

Today's Range

Now: $77.61
Low: $75.41
High: $78.46

50 Day Range

MA: $74.48
Low: $61.48
High: $84.79

2 Week Range

Now: $77.61
Low: $34.48
High: $87.19

Volume

290,434 shs

Average Volume

275,915 shs

Market Capitalization

$3.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.82
Economic and National Security Threats Create Lithium Bonanza
The U.S. and China are fighting for new sources of lithium – the linchpin of clean energy. Lithium mining operations have been declared a national emergency. Biden has ordered America's lithium supply chain to be strengthened and investors in lithium exploration companies are rejoicing. We may be entering a decades-long lithium bull run. You don't want to miss it.
Click here for the full story.